CureVac Shareholders Face Final Decision on BioNTech Takeover

Time is running out for investors in CureVac, the former mRNA pioneer, as a critical deadline approaches. The company’s acquisition by its larger rival, BioNTech, is entering its final stages, leaving shareholders with a pressing choice. Failure to act could result in holding potentially illiquid securities. What are the essential considerations in these final hours?

A Strategic Exit and Shareholder Approval

This acquisition represents more than a simple financial transaction; it signifies the closing of a chapter for Germany’s biotech industry. Having lost the initial race to develop a COVID-19 vaccine, the merger with BioNTech provides CureVac with a strategic path forward from its challenges.

Shareholders have already given their resounding approval. At an extraordinary general meeting, an overwhelming 99.16 percent voted in favor of the deal. The terms are fixed: for each CureVac share, investors will receive 0.05363 BioNTech American Depositary Shares (ADS). This arrangement grants BioNTech valuable intellectual property and settles protracted patent disputes, while offering CureVac’s investors a stake in a profitable entity.

The Imminent Deadline for Action

For most private investors, Tuesday, December 2, is the decisive day. Although the official acceptance period for BioNTech’s public exchange offer does not expire until Wednesday afternoon, the internal deadlines set by many custodian banks and brokers for client instructions end today.

Should investors sell immediately? Or is it worth buying CureVac?

The market has fully priced in the scenario. CureVac’s share price has become tightly coupled to the contractual exchange ratio, trading steadily around the €4.50 mark. Significant independent price movement is no longer expected, as the stock now effectively functions as a derivative of BioNTech’s listing.

A Stern Warning for Indecisive Investors

Market observers are issuing strong cautions against ignoring the exchange offer. Shareholders who do not tender their holdings face considerable risks:
* Delisting: Following the transaction’s completion, CureVac is expected to be delisted from the Nasdaq and European exchanges.
* Liquidity Trap: Trading any remaining shares is likely to become extremely difficult.
* Tax Complications: Investors may encounter complex tax consequences, including issues related to withholding tax.

With CureVac poised to become a fully integrated, 100%-owned subsidiary of BioNTech, its shares will cease to function as an independent investment vehicle. Shareholders are urged to immediately verify the status of their tender instructions.